Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marija Balic

Showing results (81-90 of 121) with videos related to

Pageof 13
Sort By:
NPJ Breast Cancer|August 7, 2025
Clinical impact of single-gene vs. panel sequencing in advanced HR + /HER2- breast cancer: insights and implicationsEva Valentina Klocker, Nina Dobrić, Ricarda Graf, et al.
ESMO Open|September 24, 2020
Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancerSamantha O Perakis, Sabrina Weber, Qing Zhou, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 14, 2023
Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patientsKerstin Wimmer, Monika Sachet, Cristiano Ramos, et al.
European Journal of Cancer (Oxford, England : 1990)|June 6, 2020
The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trialPeter C Dubsky, Christian F Singer, Daniel Egle, et al.
Breast Cancer Research : BCR|December 15, 2021
Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-RegistrySimon Peter Gampenrieder, Gabriel Rinnerthaler, Christoph Tinchon, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 7, 2013
Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1Ellen Heitzer, Monika Artl, Martin Filipits, et al.
Wiener Klinische Wochenschrift|September 23, 2022
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 updateGabriel Rinnerthaler, Christian Singer, Edgar Petru, et al.
Breast Cancer Research and Treatment|January 25, 2024
Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?Kerstin Wimmer, Dominik Hlauschek, Marija Balic, et al.
Breast Cancer Research and Treatment|May 5, 2024
Correction: Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?Kerstin Wimmer, Dominik Hlauschek, Marija Balic, et al.
Breast (Edinburgh, Scotland)|February 22, 2025
Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trialsKerstin Wimmer, Dominik Hlauschek, Marija Balic, et al.
Pageof 13

Showing results (81-90 of 121) with videos related to

Sort By:
Pageof 13
NPJ Breast Cancer|August 7, 2025
Clinical impact of single-gene vs. panel sequencing in advanced HR + /HER2- breast cancer: insights and implicationsEva Valentina Klocker, Nina Dobrić, Ricarda Graf, et al.
ESMO Open|September 24, 2020
Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancerSamantha O Perakis, Sabrina Weber, Qing Zhou, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 14, 2023
Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patientsKerstin Wimmer, Monika Sachet, Cristiano Ramos, et al.
European Journal of Cancer (Oxford, England : 1990)|June 6, 2020
The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trialPeter C Dubsky, Christian F Singer, Daniel Egle, et al.
Breast Cancer Research : BCR|December 15, 2021
Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-RegistrySimon Peter Gampenrieder, Gabriel Rinnerthaler, Christoph Tinchon, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 7, 2013
Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1Ellen Heitzer, Monika Artl, Martin Filipits, et al.
Wiener Klinische Wochenschrift|September 23, 2022
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 updateGabriel Rinnerthaler, Christian Singer, Edgar Petru, et al.
Breast Cancer Research and Treatment|January 25, 2024
Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?Kerstin Wimmer, Dominik Hlauschek, Marija Balic, et al.
Breast Cancer Research and Treatment|May 5, 2024
Correction: Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?Kerstin Wimmer, Dominik Hlauschek, Marija Balic, et al.
Breast (Edinburgh, Scotland)|February 22, 2025
Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trialsKerstin Wimmer, Dominik Hlauschek, Marija Balic, et al.
Pageof 13